Symbotic Inc. (SYM) Q3 2022 Earnings Conference Call August 1, 2022 5:00 PM ET

Company Participants

Will Roberts - Head-Corporate Communications

Jack Bailey - CEO

Jen Moses - CFO

Andrew Perry - Chief Commercial Officer

Raj Malik - Chief Medical Officer

Conference Call Participants

Gil Blum - Needham & Company

Kaveri Pohlman - BTIG

Tony Butler - ROTH Capital

Edward White - H.C. Wainwright

David Nierengarten - Wedbush Securities

Anupam Rama - JPMorgan

Troy Langford - Cowen

Operator

Good day, and thank you for standing by. Welcome to the G1 Therapeutics Second Quarter 2022 Financial Results Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I'd now like to hand the conference over to your first speaker for today, Mr. William Roberts. Please go ahead.

Will Roberts

Thanks Maggie. Good morning, everyone, and welcome to the G1 conference call to discuss our second quarter '22 financial results and business update. The press release on these financial results was issued this morning and can be found in the News section of our corporate website g1therapeutics.com.

On this morning's call, the team will provide a business overview of the second quarter of '22, including an update on our clinical programs and our commercial progress in that period with COSELA, which is approved and commercially available to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum etoposide continue regimen or a topotecan containing regimen for extensive stage small cell lung cancer or ES-SCL. A question-and-answer session will follow the prepared remarks.

Before I begin, I want to remind you that today's webcast contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements represent management's judgment as of today and may involve risks and uncertainties that could cause actual results to differ materially from those expressed in or implied by these statements. For more information on such risks and uncertainties, please refer to our filings with the Securities and Exchange Commission, which are available from the SEC or on our corporate website. Any forward-looking statements represent our views as of today, August 03, 2022.

Joining me on the call today are Jack Bailey, our Chief Executive Officer; Andrew Perry, our Chief Commercial Officer; Raj Malik, our Chief Medical Officer; and Jen Moses, our Chief Financial Officer.